Search results for "Screen"

showing 10 items of 1374 documents

Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation …

2012

Little information from clinical trials is available regarding the efficacy of trastuzumab treatment in subcentimetric breast carcinomas (BCs). The aim of this study was to verify the existence of correlations between HER2 and hormone receptor status, Ki67 values, grade, histotype and node involvement in a cohort of pT1a,b BCs from an area not widely covered by screening campaigns. A total of 410 pT1a,b BC formalin-fixed paraffin-embedded samples collected from eight Sicilian Anatomo-Pathological Units (APUs) were classified according to the WHO classification and tumour grading was established. Estrogen and progesterone receptor status, Ki67 labelling index and HER2 status were available. …

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industryCancerRetrospective cohort studyArticlesProgesterone Receptor StatusSettore MED/08 - Anatomia Patologicamedicine.diseaseClinical trialBreast carcinoma immunohistochemistry HER2medicine.anatomical_structureOncologyTrastuzumabInternal medicineCohortsmall size breast cancer screening campaign staging immunohistochemistrymedicineBreast carcinomabusinessLymph nodemedicine.drug
researchProduct

The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives

2019

In recent decades, non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the Western world, and the occurrence of its complications, such as hepatocellular carcinoma (HCC), has rapidly increased. Obesity and diabetes are considered not only the main triggers for the development of the disease, but also two independent risk factors for HCC. Single nucleotide polymorphisms (such as PNPLA3, TM6SF2 and MBOAT7) are related to the susceptibility to the development of HCC and its progression. Therefore, an appropriate follow-up of these patients is needed for the early diagnosis and treatment of HCC. To date, international guidelines recommend the use of ultrasonogr…

OncologyHepatocellular carcinomaDiseaseReviewlcsh:ChemistryLiver disease0302 clinical medicineDisease ScreeningRisk FactorsMass ScreeningHCClcsh:QH301-705.5SpectroscopyFatty liverLiver NeoplasmsGeneral MedicineComputer Science Applications030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyMiRNAmedicine.medical_specialtyMicro RNACarcinoma HepatocellularSingle-nucleotide polymorphismCatalysisTM6SF2Inorganic ChemistryDiabetes Complications03 medical and health sciencesDiabetes mellitusInternal medicineNAFLDmedicineAnimalsHumansObesityPhysical and Theoretical ChemistryMolecular BiologyPNPLA3Long non-conding RNAbusiness.industryOrganic Chemistrymedicine.diseasedigestive system diseasesLncRNAlcsh:Biology (General)lcsh:QD1-999businessTM6SF2Non-alcoholic fatty liver disease
researchProduct

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

2010

Summary Background Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. Methods Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and informa…

OncologyInternational CooperationUterine Cervical NeoplasmsPolymerase Chain ReactionHuman papillomaviruses ; cervical cancer0302 clinical medicineGenotypeMass ScreeningYoung adult10. No inequalityPapillomaviridaeCervical cancerAged 80 and over0303 health sciencesParaffin Embeddingmedicine.diagnostic_testAge FactorsMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyAdolescentGenotypeHPV vaccinesAdenocarcinoma03 medical and health sciencesCarcinoma AdenosquamousYoung AdultInternal medicinemedicineHumansNeoplasm InvasivenessGenetic TestingPapillomavirus VaccinesGenotyping030304 developmental biologyGenetic testingAgedRetrospective StudiesGynecologybusiness.industryPapillomavirus InfectionsBasic Medical Sciencesmedicine.diseaseCross-Sectional StudiesLogistic ModelsBIOMEDICINE AND HEALTHCAREDNA ViralLinear Array HPV Genotyping TestLinear ModelsCervarixbusinessThe Lancet. Oncology
researchProduct

Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study.

2015

Background Cancer stem cells represent a population of immature tumor cells found in most solid tumors. Their peculiar features make them ideal models for studying drug resistance and sensitivity. In this study, we investigated whether cancer stem cells isolation and in vitro sensitivity assay are feasible in a clinical setting. Methods Cancer stem cells were isolated from effusions or fresh cancer tissue of 23 patients who progressed after standard therapy failure. Specific culture conditions selected for immature tumor cells that express markers of stemness. These cells were exposed in vitro to chemotherapeutic and targeted agents. Results Cancer stem cells were extracted from liver metas…

OncologyMalemedicine.medical_specialtyLung NeoplasmsTime FactorsColorectal cancerTarget therapy drug sensitivity cancer stem cellsPopulationlcsh:MedicineAntineoplastic AgentsDrug resistanceCell SeparationCancer stem cellInternal medicinemedicineHumansIn patienteducationlcsh:ScienceAgedAged 80 and overSettore MED/04 - Patologia Generaleeducation.field_of_studyMultidisciplinaryLungbusiness.industrylcsh:RLiver NeoplasmsMiddle Agedmedicine.diseaseIn vitroClinical trialPleural EffusionDrug Combinationsmedicine.anatomical_structureLymphatic MetastasisNeoplastic Stem CellsFeasibility Studieslcsh:QFemaleDrug Screening Assays AntitumorbusinessColorectal NeoplasmsResearch Article
researchProduct

Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use

2015

Objective The aim of this study was to compare the uptake of mail-delivered tests for colorectal cancer screening. We assessed the effect of an advance notification letter and a reminder letter, and analysed the proportion of inappropriately handled tests. Materials and methods Fifteen thousand randomly selected residents of Latvia aged 50–74 years were allocated to receive one of three different test systems: either a guaiac faecal occult blood test (gFOBT) or one of two laboratory-based immunochemical tests (FIT) – FOB Gold or OC-Sensor. Half of the target population received an advance notification letter; all nonresponders were sent a reminder letter. Results The uptake of screening was…

OncologyMalemedicine.medical_specialtygenetic structuresColorectal cancerReminder Systemseducationcolorectal cancer screeningfaecal occult blood testSpecimen HandlingRandom AllocationInternal medicinemedicinePostal serviceOriginal Articles: Colorectal CancerHumansPostal ServiceEarly Detection of CancerAgedRandom allocationGynecologyHepatologybusiness.industryImmunochemistryGastroenterologyMiddle AgedPatient Acceptance of Health Caremedicine.diseasefaecal immunochemical testCorrespondence as TopicLatviaadvance notification letterTest (assessment)Colorectal cancer screeninguptakeOccult BloodFemaleFaecal occult blood testbusinessColorectal NeoplasmsGuaiacEuropean Journal of Gastroenterology & Hepatology
researchProduct

COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?

2020

The world is facing a new pandemic caused by a novel beta coronavirus (COVID 19), which causes severe respiratory coronavirus syndrome (SARS-CoV-2). Unfortunately, there are currently no US Food and Drug Administration (FDA) approved medications for the treatment of COVID-19 patients. High mortality rates in frail patients is a notable feature of the virus registered since the onset of COVID-19 pandemic. Above all, elderly patients or those with underlying chronic illnesses and compromised immune system are most at risk (1). Thus, the consideration is that the possible coexistence, in the same individual, of a cancer diagnosis and a COVID-19 infection could generate a synergistic negative p…

OncologyOpinionmedicine.medical_specialty2019-20 coronavirus outbreakCancer ResearchtherapyCoronavirus disease 2019 (COVID-19)business.industrySettore MED/06 - Oncologia MedicaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)screeningCancerCOVID-19medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282OncologyCOVID-19 cancer prognosis screening therapyInternal medicinemedicinecancerprognosisbusinessFrontiers in Oncology
researchProduct

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2…

2012

Abstract Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization. Methods: We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers. Results: There was strong evidence that the proportion of estrogen receptor (ER)-negative breast tumors decreased with age at diagnosis among BRCA1 (P-trend = 1.2 × 10−5), but increased with age at diagnosis among BRCA2, carriers (P-trend = 6.8 × 10−6). The proportion of triple-negative tumors decreased with age at diagnos…

OncologyPathologyendocrine system diseasesEpidemiologyGenes BRCA2Genes BRCA1Estrogen receptorGene mutation0302 clinical medicineCancer screeningMedicineskin and connective tissue diseasesEstrogen Receptor StatusOvarian Neoplasms0303 health sciencesMiddle Agedfemale genital diseases and pregnancy complications3. Good healthSerous fluidtriple-negative tumorsOncology030220 oncology & carcinogenesisFemaleestrogen receptorAdultmedicine.medical_specialtyBRCA1; BRCA2; breast cancer; estrogen receptor; triple-negative tumorsHereditary cancer and cancer-related syndromes Genetics and epigenetic pathways of disease [ONCOL 1]Breast NeoplasmsArticle03 medical and health sciencesbreast cancerBreast cancerSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Internal medicineHumansGenetic Predisposition to DiseaseGenetics and epigenetic pathways of disease Translational research [NCMLS 6]Germ-Line MutationAged030304 developmental biologyHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryCancerBRCA1medicine.diseaseBRCA2Neoplasm GradingbusinessOvarian cancer
researchProduct

Breath testing as a method for detecting lung cancer

2014

Early diagnosis of lung cancer is important due to high mortality in late stages of the disease. An ideal approach for population screening could be the breath analysis, due to its non-invasiveness, simplicity and cheapness. Using sensitive methods of analysis like gas chromatography/mass spectrometry in exhaled air of cancer patients were discovered some volatile organic compounds - possible candidates for cancer markers. However, these compounds were not specific for cancer cells. At the same time, integrative approaches used to analyze the exhaled breath have demonstrated high sensitivity and specificity of this method for lung cancer diagnosis. Such integrative approaches include detect…

Oncologyelectronic nosemedicine.medical_specialtyPathologyLung Neoplasms:MEDICINE [Research Subject Categories]Sensitivity and SpecificityGas Chromatography-Mass SpectrometryBreath testingInternal medicineCancer screeningBiomarkers TumormedicineHumansPharmacology (medical)Lung cancerEarly Detection of CancerNeoplasm StagingVolatile Organic CompoundsElectronic nosecancer diagnosticsbusiness.industryCancerExhalationexhaled breath analysismedicine.diseaselung cancerBreath TestsOncologyBreath gas analysisExhalationcancer screeningGas chromatographybusiness
researchProduct

Validation of monocyte distribution width decisional cutoff for sepsis detection in the acute setting

2021

not available

Oncologymedicine.medical_specialtyClinical BiochemistryMonocytesSepsisLeukocyte CountMDWSepsisInternal medicinemedicineHumansDistribution (pharmacology)Cutoffsepsis.business.industryscreeningMonocyteBiochemistry (medical)Reproducibility of ResultsHematologyGeneral Medicinemedicine.diseasemedicine.anatomical_structurebiomarkerBiomarker (medicine)businessBiomarkersCBCInternational Journal of Laboratory Hematology
researchProduct

Diagnosis of hepatocellular carcinoma (HCC) is better if early in any case.

2011

Oncologymedicine.medical_specialtyHepatocellular carcinoma Screening Liver cirrhosisbusiness.industryHepatocellular carcinomaInternal medicineInternal Medicinemedicinemedicine.diseasebusiness
researchProduct